Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

apotex corp. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - amlodipine 2.5 mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. - do not coadminister aliskiren with angiotensin receptor blockers (arbs), ace inhibitors, including amlodipine besylate and benazepril hydrochloride in patients with diabetes. - amlodipine besylate and benazepril hydrochloride is contraindicated in patients with a history of angioedema, with or without previous ace inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ace inhibitor, to amlodipine, or to any of the excipients of amlodipine besylate and benazepril hydrochloride. pregnancy category d use of drugs that act on the ras during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. potential neonatal adverse effects include sku

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. - do not coadminister aliskiren with angiotensin receptor blockers (arbs), ace inhibitors, including amlodipine besylate and benazepril hydrochloride in patients with diabetes. - amlodipine besylate and benazepril hydrochloride is contraindicated in patients with a history of angioedema, with or without previous ace inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ace inhibitor, to amlodipine, or to any of the excipients of amlodipine besylate and benazepril hydrochloride. pregnancy category d use of drugs that act on the ras during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. potential neonatal adverse effects include sku

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. - do not coadminister aliskiren with angiotensin receptor blockers (arbs), ace inhibitors, including amlodipine besylate and benazepril hydrochloride in patients with diabetes. - amlodipine besylate and benazepril hydrochloride is contraindicated in patients with a history of angioedema, with or without previous ace inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ace inhibitor, to amlodipine, or to any of the excipients of amlodipine besylate and benazepril hydrochloride. pregnancy category d use of drugs that act on the ras during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. potential neonatal adverse effects include sku

Malta - engleski - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - amlodipine, atorvastatin - film-coated tablet - amlodipine 5 mg atorvastatin 10 mg - lipid modifying agents

Malta - engleski - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - amlodipine, atorvastatin - film-coated tablet - amlodipine 10 mg atorvastatin 10 mg - lipid modifying agents

Malta - engleski - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - amlodipine besylate, valsartan - film-coated tablet - amlodipine besylate 5 mg valsartan 160 mg - agents acting on the renin-angiotensin system

Malta - engleski - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - amlodipine besylate, valsartan - film-coated tablet - amlodipine besylate 10 mg valsartan 160 mg - agents acting on the renin-angiotensin system

Malta - engleski - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - amlodipine besylate, valsartan - film-coated tablet - amlodipine besylate 5 mg valsartan 80 mg - agents acting on the renin-angiotensin system

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

physicians total care, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - amlodipine 5 mg - exforge (amlodipine and valsartan) is indicated for the treatment of hypertension. exforge may be used in patients whose blood pressure is not adequately controlled on either monotherapy. exforge may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of exforge as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the lowest dose of exforge. patients with stage 2 hypertension (moderate or severe) are at a relatively higher risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monothe